Pharvaris
PHVS
31.28
-0.38
-1.20%
Pharvaris
US · PHVS
#2729 by market cap
Listed 2021
31.28
-0.38
-1.20%
Periodic snapshot; not a real-time feed.
· 2026-11-20 20:01
Recent news
-
Morgan Stanley Maintains Pharvaris(PHVS.US) With Buy Rating, Maintains Target Price $62Market Newswire · 2026/11/9
-
Rating change
H.C. Wainwright Maintains Pharvaris(PHVS.US) With Buy Rating, Maintains Target Price $60Market Newswire · 2026/10/6
-
Rating change
Morgan Stanley Maintains Pharvaris(PHVS.US) With Buy Rating, Maintains Target Price $41Market Newswire · 2026/6/15
-
Rating change
Analysts Offer Insights on Healthcare Companies: Pharvaris (PHVS), Fractyl Health, Inc. (GUTS) and Ascendis Pharma (ASND)TipRanks · 2026/10/19
-
Earnings Flash (PHVS) Pharvaris Posts Q3 Loss 0.67 Euros a Share, Vs. FactSet Est of 0.77 Euro LossMT Newswires · 2026/11/12
-
Rating change
BofA Securities Maintains Pharvaris(PHVS.US) With Hold Rating, Raises Target Price to $35Market Newswire · 2026/7/29
-
Oppenheimer Initiates Pharvaris(PHVS.US) With Buy Rating, Announces Target Price $75Market Newswire · 2026/11/13
-
Rating change
Morgan Stanley Maintains Pharvaris(PHVS.US) With Buy Rating, Raises Target Price to $46Market Newswire · 2026/6/25
-
Rating change
Morgan Stanley Maintains Pharvaris(PHVS.US) With Buy Rating, Cuts Target Price to $30.4Market Newswire · 2026/5/18
-
Rating change
A Quick Look at Today's Ratings for Pharvaris(PHVS.US), With a Forecast Between $38 to $55Market Newswire · 2026/8/13
-
Wells Fargo Maintains Pharvaris(PHVS.US) With Buy Rating, Maintains Target Price $65Market Newswire · 2026/11/13
-
Rating change
A Quick Look at Today's Ratings for Pharvaris(PHVS.US), With a Forecast Between $44 to $79Market Newswire · 2026/9/10
-
Rating change
BofA Securities Upgrades Pharvaris(PHVS.US) to Buy Rating, Maintains Target Price $44Market Newswire · 2026/10/23
-
Rating change
JonesTrading Maintains Pharvaris(PHVS.US) With Buy Rating, Maintains Target Price $52Market Newswire · 2026/8/29
-
Rating change
Pharvaris (PHVS) Gets a Buy From H.C. WainwrightTipRanks · 2026/9/22
-
Rating change
Oppenheimer Maintains Pharvaris(PHVS.US) With Buy Rating, Maintains Target Price $50Market Newswire · 2026/5/13
-
Rating change
BofA Securities Maintains Pharvaris(PHVS.US) With Hold Rating, Raises Target Price to $33Market Newswire · 2026/5/14
-
Rating change
Wells Fargo Initiates Pharvaris(PHVS.US) With Buy Rating, Announces Target Price $55Market Newswire · 2026/7/15
-
RBC Capital Maintains Pharvaris(PHVS.US) With Buy Rating, Raises Target Price to $63Market Newswire · 2026/11/14
-
Rating change
Morgan Stanley Maintains Pharvaris(PHVS.US) With Buy Rating, Maintains Target Price $46Market Newswire · 2026/9/8
-
Rating change
A Quick Look at Today's Ratings for Pharvaris(PHVS.US), With a Forecast Between $46 to $74Market Newswire · 2026/5/13
-
Wells Fargo Maintains Pharvaris(PHVS.US) With Buy Rating, Maintains Target Price $65Market Newswire · 2026/10/15
-
Morgan Stanley Maintains Pharvaris(PHVS.US) With Buy Rating, Maintains Target Price $62Market Newswire · 2026/10/26
-
Rating change
Analysts Offer Insights on Healthcare Companies: Amylyx Pharmaceuticals Inc (AMLX), BioAge Labs, Inc. (BIOA) and Pharvaris (PHVS)TipRanks · 2026/5/10
-
Rating change
Wedbush Maintains Pharvaris(PHVS.US) With Buy Rating, Maintains Target Price $42Market Newswire · 2026/5/13
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-11-20 20:01:10 · For reference only, not investment advice and not tailored to your situation.
Pharvaris discussion 0 comments